Harbour BioMed

HBM Alpha Therapeutics is a biotechnology company focused on developing antibody therapeutics for rare genetic diseases, specifically congenital adrenal hyperplasia and polycystic ovary syndrome. The company aims to create precise treatments that address these conditions and may also extend its therapeutic applications to other endocrinological diseases associated with dysregulation of the hypothalamic-pituitary-adrenal axis. Through its health technology platform, HBM Alpha Therapeutics seeks to enhance the healthcare sector's ability to provide targeted therapies for endocrine disorders, thereby improving patient outcomes in these specialized areas.

Harbour Antibodies BV, established in 2006 and based in Rotterdam, the Netherlands, specializes in the production of antibodies and VH domains for therapeutic applications. The company utilizes advanced transgenic mouse technology to create high-affinity human antibodies, notably offering two types of transgenic mice: those that produce conventional tetrameric antibodies composed of two heavy and two light chains (H2L2) and those that generate heavy chain-only antibodies (HCAbs). The HCAbs allow for the development of soluble human VH domains, enabling the construction of innovative multi-functional molecules. Harbour Antibodies has positioned itself as a key player in the biotechnology sector, providing its transgenic mouse lines to licensing partners for further research and development. As of 2016, it operates as a subsidiary of Harbour BioMed.